BRIEF — AstraZeneca's Efzimfotase alfa Granted Priority Review In U.S.
Sept 18 (Reuters) — AstraZeneca PLC: Astrazeneca: Efzimfotase Alfa Granted Priority Review In Us As Treatment For Patients With Hypophosphatasia Aged 2 Years And Older Astrazeneca - Fda Decision On Efzimfotase Alfa Expected In First Half Of 2027 Source text:... Further company coverage: AZN.L (Reuters.Briefs@thomsonreuters.com;)
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.